Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT00697749 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Start date: April 1999
Phase: Phase 3
Study type: Interventional

This study compares the immunogenicity and safety of the novel adjuvanted HBV vaccine and Engerix™-B administered to subjects who were positively identified as having the HLA-DQ2 genotype

NCT ID: NCT00697554 Completed - Hepatitis B Clinical Trials

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Start date: January 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to enroll pre-liver transplant patients who will be vaccinated with either the novel adjuvanted HBV vaccine or double doses of Engerix™-B. The immunogenicity and safety of the novel adjuvanted vaccine will be compared to Engerix™-B as the control vaccine

NCT ID: NCT00697242 Completed - Hepatitis B Clinical Trials

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Start date: January 1994
Phase: Phase 3
Study type: Interventional

In the present study the immunogenicity, reactogenicity and safety of recombinant hepatitis B vaccines with and without MPL will be evaluated in older healthy subjects

NCT ID: NCT00697229 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Start date: September 1992
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, immunogenicity and reactogenicity of MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following two different schedules: 0, 2 months and 0, 6 months

NCT ID: NCT00697125 Completed - Hepatitis B Clinical Trials

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Start date: June 1993
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

NCT ID: NCT00696917 Completed - Hepatitis B Clinical Trials

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Start date: April 1999
Phase: Phase 3
Study type: Interventional

This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL vaccine and to compare their safety and immunogenicity with that of Engerix™-B.

NCT ID: NCT00695019 Completed - Clinical trials for Hepatitis C, Chronic

Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether lozenges of interferon-alpha that are dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who had a complete virologic response after receiving a combination of injected interferon-alpha and oral ribavirin.

NCT ID: NCT00693186 Completed - Hepatitis B Clinical Trials

A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Start date: October 2008
Phase: Phase 3
Study type: Interventional

Primary objective: - To describe in subjects vaccinated with 3 doses of HEXAVAC® or 3 doses of INFANRIX®-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre ≥10 mIU/mL 1 month after a booster dose of either HBVaxPRO® 5 µg or Engerix B® 10 µg . Secondary objectives: - Additional immunogenicity assessments - Standard safety assessment.

NCT ID: NCT00687999 Completed - Insulin Resistance Clinical Trials

NIDDM and IR in Combination Therapy for CHC

Start date: December 2005
Phase: N/A
Study type: Interventional

The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of combination therapy on HOMA IR

NCT ID: NCT00687180 Completed - Clinical trials for Autoimmune Hepatitis

Mycophenolate vs Azathioprin in Autoimmune Hepatitis

Start date: n/a
Phase: Phase 4
Study type: Interventional

A study with 20 de novo patients with autoimmune hepatitis, 10 receiving azathioprin and 10 receiving mycophenolat mofetil.